Skip to main content

Table 2 Laboratory findings and diagnostic patterns of patients with gout or calcium pyrophosphate deposition disease in prosthetic joints

From: Crystal-induced arthritis in prosthetic joints: a systematic review of clinical features, diagnosis, management, and outcomes

 

Prevalence (%) *

Median (IQR)

Laboratory Findings

  

 Serum WBC (103/µL)

27/44 (61.4)

12.4 (8.2–14.4)

 ESR (mm/h)

24/44 (54.5)

67.0 (33.5–97.5)

 CRP (mg/L)

29/44 (65.9)

59.0 (14.2–215.8)

 Serum urate (mg/dL)

16/44 (36.4)

8.9 (8.1–10.4)

 Synovial fluid WBC (103/µL)

30/44 (68.2)

22.0 (9.5–40.1)

 Synovial fluid PMNs (%)

25/44 (56.8)

90.0 (81.5–95.0)

Type of Crystals

  

 Monosodium urate

25/44 (56.8)

 

 CPPD

20/44 (45.5)

 

 Hydroxyapatite

1/44 (2.3)

 

Time from Prosthetic Surgery to Onset of Symptoms (years)

44/44 (100)

7.0 (0.19–10.0)

Time from Therapeutic Initiation to Symptomatic Resolution (days)

31/44 (70.5)

3.0 (1.0–6.0)

Means of Diagnosis

  

 Arthrocentesis

30/41 (68.2)

 

 Synovial biopsy or synovectomy

3/41 (7.3)

 

 Arthrocentesis, followed by synovial biopsy or synovectomy

8/41 (19.5)

 
  1. Abbreviations CPPD, calcium pyrophosphate dihydrate crystal deposition disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; PMN, polymorphonuclear; WBC, white blood cell
  2. * Prevalence here is defined as the number of cases reported the variable divided by the number of the total cases